Author

Liam Kelley

Harvard University

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Organism:human· 1 Assay:metabolomics· 1 Organism:mouse· 1

Frequent Co-Authors

Alcides Euzebio Tavares XavieriD· 1 shared Alessandro PreteiD· 1 shared Andris JankevicsiD· 1 shared Angela E. TayloriD· 1 shared Antoine TabariniD· 1 shared Betül Haykir· 1 shared Catherine L. WinderiD· 1 shared Claudio Henrique T. RibeiroiD· 1 shared

Activity by Year

2025-2025 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Alcides Euzebio Tavares XavierORCID

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

Glutamine antagonism suppresses tumor growth in adrenocortical carcinoma through inhibition of de novo nucleotide biosynthesis

Vasileios Chortis, Kleiton Silva Borges, Cong-Hui Yao, Claudio Henrique T. Ribeiro, Luís Fernando Peinado Nagano, Mesut Berber, Alessandro Prete, Lukáš Najdekr, Michail E. Klontzas, Andris Jankevics, Pedro Henrique Vendramini, Jean Lucas Kremer, Liam Kelley, Sathuwarman Raveenthiraraj, Alcides Euzebio Tavares Xavier, , David T. Breault

This study identifies glutamine antagonism as a therapeutic strategy for adrenocortical carcinoma by inhibiting de novo nucleotide biosynthesis and inducing DNA damage.

bioRxiv · Sep 28, 2025 · PreprintCancer Biology